154 related articles for article (PubMed ID: 37921752)
1. Preclinical Safety Assessment of Gadopiclenol: A High-Relaxivity Macrocyclic Gadolinium-Based MRI Contrast Agent.
Gendron C; Bourrinet P; Dencausse A; Fretellier N
Invest Radiol; 2024 Feb; 59(2):108-123. PubMed ID: 37921752
[TBL] [Abstract][Full Text] [Related]
2. Toxicological safety evaluation of gadobutrol.
Wack C; Steger-Hartmann T; Mylecraine L; Hofmeister R
Invest Radiol; 2012 Nov; 47(11):611-23. PubMed ID: 23011188
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study).
Hao J; Bourrinet P; Desché P
Invest Radiol; 2019 Jul; 54(7):396-402. PubMed ID: 30870257
[TBL] [Abstract][Full Text] [Related]
4. Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System.
Bendszus M; Roberts D; Kolumban B; Meza JA; Bereczki D; San-Juan D; Liu BP; Anzalone N; Maravilla K
Invest Radiol; 2020 Mar; 55(3):129-137. PubMed ID: 31917762
[TBL] [Abstract][Full Text] [Related]
5. Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure.
Fretellier N; Rasschaert M; Bocanegra J; Robert P; Factor C; Seron A; Idée JM; Corot C
Invest Radiol; 2021 Dec; 56(12):826-836. PubMed ID: 34091462
[TBL] [Abstract][Full Text] [Related]
6. Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine.
Violas X; Rasschaert M; Santus R; Factor C; Corot C; Catoen S; Idée JM; Robert P
Invest Radiol; 2022 Feb; 57(2):130-139. PubMed ID: 34411032
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body.
Hao J; Pitrou C; Bourrinet P
Invest Radiol; 2024 Feb; 59(2):124-130. PubMed ID: 37812485
[TBL] [Abstract][Full Text] [Related]
8. Detection of Brain Metastases by Contrast-Enhanced MRI: Comparison of Gadopiclenol and Gadobenate in a Mouse Model.
Robert P; Vives V; Rasschaert M; Hao J; Soares M; Lemaître M; Dencausse A; Catoen S
Invest Radiol; 2024 Feb; 59(2):131-139. PubMed ID: 37921777
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity.
Robic C; Port M; Rousseaux O; Louguet S; Fretellier N; Catoen S; Factor C; Le Greneur S; Medina C; Bourrinet P; Raynal I; Idée JM; Corot C
Invest Radiol; 2019 Aug; 54(8):475-484. PubMed ID: 30973459
[TBL] [Abstract][Full Text] [Related]
10. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA; Kolumban B; Hutóczki G; Dziadziuszko K; Bereczki D; Bago A; Pichiecchio A
Invest Radiol; 2023 May; 58(5):307-313. PubMed ID: 36729404
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
Fries P; Massmann A; Robert P; Corot C; Laschke MW; Schneider G; Buecker A; Müller A
Invest Radiol; 2019 Sep; 54(9):549-558. PubMed ID: 31033675
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
14. Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.
Steger-Hartmann T; Graham PB; Müller S; Schweinfurth H
Invest Radiol; 2006 May; 41(5):449-59. PubMed ID: 16625108
[TBL] [Abstract][Full Text] [Related]
15. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).
Döhr O; Hofmeister R; Treher M; Schweinfurth H
Invest Radiol; 2007 Dec; 42(12):830-41. PubMed ID: 18007155
[TBL] [Abstract][Full Text] [Related]
16. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years.
Jurkiewicz E; Tsvetkova S; Grinberg A; Pasquiers B
Invest Radiol; 2022 Aug; 57(8):510-516. PubMed ID: 35318970
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.
Li Y; Gao S; Jiang H; Ayat N; Laney V; Nicolescu C; Sun W; Tweedle MF; Lu ZR
Invest Radiol; 2022 Oct; 57(10):639-654. PubMed ID: 35703463
[TBL] [Abstract][Full Text] [Related]
19. Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide.
Funke SKI; Factor C; Rasschaert M; Lezius L; Sperling M; Karst U; Robert P
Radiology; 2022 Oct; 305(1):179-189. PubMed ID: 35727155
[TBL] [Abstract][Full Text] [Related]
20. Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate as used in cosmetics.
Elmore AR
Int J Toxicol; 2005; 24 Suppl 2():51-111. PubMed ID: 16154915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
